Skip to main content
Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
230.02
+3.82 (1.69%)
At close: Jun 26, 2026, 4:00 PM EDT
228.07
-1.95 (-0.85%)
After-hours: Jun 26, 2026, 6:07 PM EDT

Jazz Pharmaceuticals Revenue by Segment
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Neuroscience
2.96B 2.88B 2.82B 2.75B 2.72B 2.70B 2.66B 2.63B
Neuroscience Growth
8.81% 6.68% 6.01% 4.40% 3.25% -0.35% -3.68% -5.92%
Oncology
1.23B 1.13B 1.08B 1.08B 1.08B 1.11B 1.09B 1.07B
Oncology Growth
13.79% 1.56% -0.93% 1.04% 3.77% 9.47% 13.26% 15.16%

Oncology Revenue Breakdown
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Rylaze Enrylaze
412.39M 402.92M 396.25M 395.16M 402.33M 410.85M 411.11M 417.19M
Rylaze Enrylaze Growth
2.50% -1.93% -3.61% -5.28% -2.12% 4.22% 10.08% 21.95%
Zepzelca
345.28M 307.31M 295.20M 301.75M 308.25M 320.32M 316.00M 308.15M
Zepzelca Growth
12.01% -4.06% -6.58% -2.08% 3.63% 10.63% 9.92% 10.13%
Defitellio Defibtrotide
206.13M 199.39M 198.17M 212.24M 209.55M 216.57M 210.00M 191.91M
Defitellio Defibtrotide Growth
-1.63% -7.93% -5.63% 10.59% 8.80% 17.70% 20.99% 9.48%
Vyxeos
143.77M 146.71M 165.23M 161.96M 160.12M 162.60M 156.26M 151.77M
Vyxeos Growth
-10.21% -9.77% 5.74% 6.71% 12.11% 10.24% 19.42% 15.78%
Modeyso
88.97M 47.57M 11.03M - - - - -

Neroscience Revenue Breakdown
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Xywav
1.72B 1.66B 1.59B 1.55B 1.50B 1.47B 1.41B 1.35B
Xywav Growth
14.49% 12.48% 13.00% 14.58% 14.67% 15.73% 15.77% 18.46%
Epidiolex
1.09B 1.06B 1.05B 996.07M 991.44M 972.42M 938.00M 900.15M
Epidiolex Growth
10.07% 8.92% 11.63% 10.66% 15.92% 15.02% 15.54% 13.32%
Xyrem
139.99M 146.03M 157.54M 179.99M 206.83M 233.82M 291.25M 358.24M
Xyrem Growth
-32.31% -37.54% -45.91% -49.76% -54.63% -58.96% -59.01% -57.42%
Sativex
10.87M 16.28M 19.95M 19.78M 21.55M 18.88M 18.84M 18.88M
Sativex Growth
-49.56% -13.77% 5.87% 4.76% 40.80% -4.02% -2.13% 5.81%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.